tickertape
← golden set

BMY

BRISTOL MYERS SQUIBB COHealthcare
10-K for period ending 2025-12-31filed 2026-02-11accession 0000014272-26-000004filing on sec.gov ↗

answer key

fieldSEC valueXBRL conceptprinted on
Total revenue$48.2BRevenuesTotal Revenues
Operating income-not reportednot in this filing's XBRL
Net income attributable to the company$7.1BNetIncomeLossNet earnings/(loss) attributable to BMS
Diluted EPS$3.46EarningsPerShareDilutedDiluted
Cash and cash equivalents$10.2BCashAndCashEquivalentsAtCarryingValueCash and cash equivalents
Total assets$90.0BAssetsTotal Assets · Total Liabilities and Equity
Total liabilities$71.5BLiabilitiesTotal Liabilities
Total shareholders' equity attributable to the company$18.5BStockholdersEquityTotal BMS Shareholders’ Equity
Net cash from operating activities$14.2BNetCashProvidedByUsedInOperatingActivitiesNet cash provided by operating activities
Net cash from investing activities-$4.1BNetCashProvidedByUsedInInvestingActivitiesNet cash provided by/(used in) investing activities
Net cash from financing activities-$10.3BNetCashProvidedByUsedInFinancingActivitiesNet cash provided by/(used in) financing activities

Income statement

table #82 · score 49.5 vs 22.5 runner-up · in millions
Year Ended December 31,
202520242023
Net product sales46,75646,77843,778
Alliance and other revenues1,4381,5221,228
Total Revenues48,19448,30045,006
Cost of products sold(a)13,93613,96810,693
Selling, general and administrative7,2678,4147,772
Research and development9,95111,1599,299
Acquired IPRD3,72113,373913
Amortization of acquired intangible assets3,3178,8729,047
Other (income)/expense, net674893(1,158)
Total Expenses38,86656,67936,566
Earnings/(Loss) before income taxes9,328(8,379)8,440
Income tax provision2,272554400
Net earnings/(loss)7,055(8,933)8,040
Noncontrolling Interest21515
Net earnings/(loss) attributable to BMS7,054(8,948)8,025
Earnings/(Loss) per common share:
Basic3.47(4.41)3.88
Diluted3.46(4.41)3.86

Balance sheet

table #84 · score 52.8 vs 21 runner-up · in millions
December 31,
ASSETS20252024
Current assets:
Cash and cash equivalents10,20910,346
Marketable debt securities464513
Receivables11,41410,747
Inventories2,6902,557
Other current assets4,6135,617
Total Current assets29,39029,780
Property, plant and equipment7,5437,136
Goodwill21,75421,719
Other intangible assets19,10323,307
Deferred income taxes5,3784,236
Marketable debt securities396320
Other non-current assets6,4746,105
Total Assets90,03892,603
LIABILITIES
Current liabilities:
Short-term debt obligations2,2612,046
Accounts payable3,5753,602
Other current liabilities17,58118,126
Total Current liabilities23,41723,774
Deferred income taxes222369
Long-term debt42,85047,603
Other non-current liabilities5,0434,469
Total Liabilities71,53376,215
Commitments and Contingencies (Note 20)
EQUITY
Bristol-Myers Squibb Company Shareholders’ Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 2,510 in 2025 and 2,868 in 2024, liquidation value of $50 per share--
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.9 billion issued in 2025 and 2024292292
Capital in excess of par value of stock46,38746,024
Accumulated other comprehensive loss(1,524)(1,238)
Retained earnings16,89614,912
Less cost of treasury stock - 887 million common shares in 2025 and 894 million common shares in 2024(43,579)(43,655)
Total BMS Shareholders’ Equity18,47316,335
Noncontrolling interest3353
Total Equity18,50616,388
Total Liabilities and Equity90,03892,603

Cash flow statement

table #85 · score 54.5 vs 10 runner-up · in millions
Year Ended December 31,
202520242023
Cash Flows From Operating Activities:
Net earnings/(loss)7,055(8,933)8,040
Adjustments to reconcile net earnings/(loss) to net cash provided by operating activities:
Depreciation and amortization, net4,0119,6009,760
Deferred income taxes(965)(2,089)(3,288)
Stock-based compensation553507518
Impairment charges1,0982,963255
Divestiture gains and royalties(1,165)(1,119)(884)
Acquired IPRD3,72113,373913
Equity investment (gains)/losses, net(280)(16)160
Contingent consideration fair value adjustments351--
Other adjustments23294300
Changes in operating assets and liabilities:
Receivables(295)264(995)
Inventories(184)(486)(751)
Accounts payable(2)184198
Rebates and discounts(441)1,484904
Income taxes payable(4)(1,260)(603)
Other471624(667)
Net cash provided by operating activities14,15615,19013,860
Cash Flows From Investing Activities:
Sale and maturities of marketable debt securities1,9751,122733
Purchase of marketable debt securities(2,000)(769)(1,774)
Proceeds from sales of equity investments77265215
Capital expenditures(1,311)(1,248)(1,209)
Divestiture and other proceeds1,0711,099909
Acquisition and other payments, net of cash acquired(3,944)(21,821)(1,169)
Net cash provided by/(used in) investing activities(4,132)(21,352)(2,295)
Cash Flows From Financing Activities:
Proceeds from issuance of short-term debt obligations-2,987-
Repayments of short-term debt obligations-(3,000)-
Other short-term financing obligations, net2599(120)
Proceeds from issuance of long-term debt5,74012,8834,455
Repayments of long-term debt(10,940)(2,873)(3,879)
Repurchase of common stock--(5,155)
Dividends(5,045)(4,863)(4,744)
Stock option proceeds and other, net(128)(106)27
Net cash provided by/(used in) financing activities(10,348)5,127(9,416)
Effect of exchange rates on cash, cash equivalents and restricted cash195(137)45
Increase/(decrease) in cash, cash equivalents and restricted cash(129)(1,172)2,194
Cash, cash equivalents and restricted cash at beginning of period10,34711,5199,325
Cash, cash equivalents and restricted cash at end of period10,21810,34711,519